NCT01795677

JAK2 Inhibitors RUXOLITINIB in Patients With Myelofibrosis

JAK2 Inhibitors RUXOLITINIB in Patients With High or Intermediate Risk Primary or Secondary Myelofibrosis Eligible for Allogeneic Stem Cell Transplantation: a Prospective Multicentric Phase II Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 78 (actual)
• Sponsor: French Innovative Leukemia Organisation · Academic / Other
• Sex: All
• Age: 18 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with primary or secondary myelofibrosis : a prospective phase II

Detailed description

JAK2 inhibitor RUXOLITINIB before allogeneic hematopoietic stem cell transplantation (HSCT) in patients with primary or secondary myelofibrosis

Conditions

• Myelofibrosis

Interventions

Type	Name	Description
DRUG	Ruxolotinib	Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor

Timeline

• Start date: 2012-12-01
• Primary completion: 2018-05-01
• Completion: 2019-03-01
• First posted: 2013-02-21
• Last updated: 2022-07-27

Locations

1 site across 1 country: France